Skip to main content
LFCR
NASDAQ Life Sciences

Activist Investor 22NW Demands Full Preferred Stock Redemption, Threatens Litigation

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Pharmaceutical Stocks · Healthcare
Sentiment info
Negative
Importance info
9
Price
$5.09
Mkt Cap
$190.923M
52W Low
$3.625
52W High
$8.98
52W Position info
40% above low
Off High info
43% below high
Rel. Volume info
0.5× avg
Market data snapshot near publication time

LFCR sits 40% above its 52-week low of $3.625.

Summary

Activist investor 22NW Fund has demanded the full cash redemption of its Series A Preferred Stock holdings by December 28, 2026, and plans to amend its lawsuit against Lifecore Biomedical over redemption restrictions.


Key Events · Ownership and Investor Activity · LFCR

  • Activist Demands Full Preferred Stock Redemption

    22NW Fund has submitted an optional redemption notice for its entire Series A Preferred Stock holdings, convertible into 2,711,218 common shares.

  • Redemption Date Set

    The full cash redemption of 22NW's preferred stock is scheduled for December 28, 2026.

  • Legal Action Threat

    22NW intends to amend its existing complaint against Lifecore Biomedical, alleging a breach of the Securities Purchase Agreement due to credit agreement restrictions on redemptions.

  • Significant Liquidity Challenge

    This redemption demand contributes to a total of $52.1 million in preferred stock redemptions the company faces by year-end, an amount that exceeds its current liquidity.


Analysis · LFCR · Life Sciences

The activist investor 22NW Fund has formally demanded the cash redemption of its entire Series A Preferred Stock holdings, which, when combined with other preferred stock redemptions, totals $52.1 million that Lifecore Biomedical must pay by year-end. This amount significantly exceeds the company's current liquidity, as disclosed in a concurrent 8-K filing, creating severe financial pressure. Furthermore, 22NW plans to amend its existing lawsuit against the company, alleging a breach of contract related to redemption restrictions, adding a layer of legal risk and uncertainty to the company's already strained financial position.

How filings like this one have moved

In the 30 days to Nov 6, 2026, 51.2% of the 201 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.73%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, LFCR was trading at $5.09 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $190.9M. The 52-week trading range was $3.63 to $8.98. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

LFCR - Latest Insights

LFCR
Nov 04, 2026, 7:13 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $6.38
Real-time Price: $6.36 info
Change: -$0.0204 (-0.32%) info
Market Cap: $241.081M info
LFCR
Oct 30, 2026, 5:26 PM EDT
Filing Type: PREM14A
Importance Score:
8
Price at Filing: $6.40
Real-time Price: $6.36 info
Change: -$0.040 (-0.63%) info
Market Cap: $241.081M info
LFCR
Sep 29, 2026, 4:15 PM EDT
Filing Type: SCHEDULE 13D/A
Importance Score:
7
Price at Filing: $6.52
Real-time Price: $6.36 info
Change: -$0.160 (-2%) info
Market Cap: $241.081M info
LFCR
Sep 28, 2026, 5:41 PM EDT
Filing Type: SCHEDULE 13D/A
Importance Score:
7
Price at Filing: $6.62
Real-time Price: $6.36 info
Change: -$0.260 (-4%) info
Market Cap: $241.081M info
LFCR
Sep 28, 2026, 8:56 AM EDT
Filing Type: DEFA14A
Importance Score:
9
Price at Filing: $4.30
Real-time Price: $6.36 info
Change: +$2.06 (+48%) info
Market Cap: $241.081M info